Takeuchi H, Fujii H, Ando N, et al. Validation study of radio-guided sentinel lymph node navigation in esophageal cancer. Ann Surg. 2009;249:757–63.
Akutsu Y, Kato K, Igaki H, et al. The prevalence of overall and initial lymph node metastases in clinical t1n0 thoracic esophageal cancer: from the results of jcog0502, a prospective multicenter study. Ann Surg. 2016;264:1009–15.
Matsuda S, Takeuchi M, Kawakubo H, et al. Lymph node metastatic patterns and the development of multidisciplinary treatment for esophageal cancer. Dis Esophagus. 2023;36:6.
Tsuji T, Matsuda S, Takeuchi M, et al. Updates of perioperative multidisciplinary treatment for surgically resectable esophageal cancer. Jpn J Clin Oncol. 2023;53:645–52.
Ozawa S, Uchi Y, Ando T, et al. Essential updates 2020/2021: recent topics in surgery and perioperative therapy for esophageal cancer. Ann Gastroenterol Surg. 2023;7:346–57.
Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.
Kato K, Ito Y, Daiko H, et al. A randomized controlled phase III trial comparing doublet chemotherapy, triplet chemotherapy, and doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced esophageal cancer: the JCOG1109 NExT study. Lancet. 2024;404:55–66.
Matsuda S, Kitagawa Y, Okui J, et al. Old age and intense chemotherapy exacerbate negative prognostic impact of postoperative complication on survival in patients with esophageal cancer who received neoadjuvant therapy: a nationwide study from 85 Japanese esophageal centers. Esophagus. 2023;20:445–54.
Kataoka K, Takeuchi H, Mizusawa J, et al. Prognostic impact of postoperative morbidity after esophagectomy for esophageal cancer: exploratory analysis of JCOG9907. Ann Surg. 2017;265:1152–7.
Udagawa H, Ueno M, Shinohara H, et al. Shoud lymph nodes along the thoracic duct be dissected routinely in radical esophagectomy? Esophagus. 2014;11:204–10.
Matsuda S, Kawakubo H, Takeuchi H, Mayanagi S, et al. Prognostic impact of thoracic duct lymph node metastasis in esophageal squamous cell carcinoma. Ann Gastroenterol Surg. 2021;5:321–30.
Matsuda S, Takeuchi H, Kawakubo H, et al. Clinical outcome of transthoracic esophagectomy with thoracic duct resection: number of dissected lymph node and distribution of lymph node metastasis around the thoracic duct. Medicine. 2016;95:e3839.
Matsuda S, Kawakubo H, Takeuchi H, et al. Minimally invasive oesophagectomy with extended lymph node dissection and thoracic duct resection for early-stage oesophageal squamous cell carcinoma. BJS. 2020;107:705–11.
Tanaka K, Yamasaki M, Sugimura K, et al. Thoracic duct resection has a favorable impact on prognosis by preventing hematogenous spread of esophageal cancer cells: a multi-institutional analysis of 2269 patients. Ann Surg Oncol. 2021;28:4402–10.
Oshikiri T, Takiguchi G, Miura S, et al. Thoracic duct resection during esophagectomy does not contribute to improved prognosis in esophageal squamous cell carcinoma: a propensity score matched-cohort study. Ann Surg Oncol. 2019;26:4053–61.
Matsuda S, Takeuchi M, Kawakubo H, et al. Oncological and physiological impact of thoracic duct resection in esophageal cancer. Dis Esophagus. 2023;36:15.
Japan Esophageal Society. Japanese classification of esophageal cancer, tenth edition: part I. Esophagus. 2009;6:1–25.
Japan Esophageal Society. Japanese classification of esophageal cancer, tenth edition: parts II and III. Esophagus. 2009;6:71–94.
van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.
Yamamoto S, Kato K, Daiko H, et al. Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E). Future Oncol. 2020;16:1351–7.
Matsuda S, Yamamoto S, Kato K, et al. FRONTiER: a feasibility trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinoma (JCOG1804E)—short-term results for cohorts C and D. J Clin Oncol. 2022;40(4_suppl):286.
Kwan TT, Bardia A, Spring LM, et al. A digital RNA signature of circulating tumor cells predicting early therapeutic response in localized and metastatic breast cancer. Cancer Discov. 2018;8:1286–99.
Corcoran RB, Chabner BA. Application of cell-free DNA Analysis to cancer treatment. N Eng J Med. 2018;379:1754–65.
Morimoto Y, Matsuda S, Kawakubo H, et al. Tumor burden monitoring with circulating tumor DNA during treatment in patients with esophageal squamous cell carcinoma. Ann Surg Oncol. 2023;30:3747–56.
Ohkura Y, Ueno M, Iizuka T, et al. Effectiveness of lymphadenectomy along the thoracic duct for radical esophagectomy. Esophagus. 2022;19:85–94.
Schurink B, Defize IL, Mazza E, et al. Two-field lymphadenectomy during esophagectomy: the presence of thoracic duct lymph nodes. Ann Thorac Surg. 2018;106:435–9.
Imamura M, Shimada Y, Kanda T, et al. Hemodynamic changes after resection of thoracic duct for en bloc resection of esophageal cancer. Surg Today. 1992;22:226–32.
Aiko S, Yoshizumi Y, Matsuyama T, et al. Influences of thoracic duct blockage on early enteral nutrition for patients who underwent esophageal cancer surgery. J Thorac Cardiovasc Surg. 2003;51:263–71.
Defize IL, Gorgels SMC, Mazza E, et al. The Presence of metastatic thoracic duct lymph nodes in western esophageal cancer patients: a multinational observational study. Ann Thorac Surg. 2022;113:429–35.
Yoshida N, Nagai Y, Baba Y, et al. Effect of resection of the thoracic duct and surrounding lymph nodes on short- and long-term and nutritional outcomes after esophagectomy for esophageal cancer. Ann Surg Oncol. 2019;26:1893–900.
Nishimura E, Matsuda S, Kawakubo H, et al. The impact of thoracic duct resection on the long-term body composition of patients who underwent esophagectomy for esophageal cancer and survived without recurrence. Dis Esophagus. 2023;36:02.
留言 (0)